Immuno-oncology is a top priority for EMD Serono, Inc., the biopharmaceutical business of Merck KGaA,
Darmstadt, Germany, in the US and Canada, and Pfizer Inc. The global strategic alliance between Merck KGaA,
Darmstadt, Germany, and Pfizer Inc, New York, US, enables the companies to benefit from each other’s
strengths and capabilities. The immuno-oncology Alliance jointly developed and commercialized avelumab, an
anti-PDL1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany.

 

Bavencio-1L urothelial carcinoma Maintenance core visual aid
An image Download File
Bavencio- merkel cell carcinoma Core Visual Aid
An image Download File
Bavencio -renal cell carcinoma Core Visual Aid
An image Download File
Bavencio-renal cell carcinoma- Therapy Management Guide
An image Download File
Dosing and Treatment Management Guide- Bavencio (merkel cell carcinoma and urothelial carcinoma)- with PI
An image Download File
Bavencio-1L urothelial carcinoma Maintenance Patient Brochure
An image Download File
Bavencio Prescribing Information
An image Download File